Elanco Animal Health (NYSE:ELAN) Stock Price Down 4.6%

Elanco Animal Health Incorporated (NYSE:ELAN)’s share price was down 4.6% on Friday . The stock traded as low as $12.94 and last traded at $12.94. Approximately 1,947,957 shares traded hands during trading, a decline of 55% from the average daily volume of 4,348,066 shares. The stock had previously closed at $13.57.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ELAN. Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. The Goldman Sachs Group raised their price objective on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th. Stifel Nicolaus raised Elanco Animal Health from a “hold” rating to a “buy” rating and boosted their target price for the company from $13.00 to $20.00 in a research note on Friday, January 5th. Finally, Barclays raised their price target on Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Elanco Animal Health Stock Down 5.9 %

The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. The company has a market capitalization of $6.30 billion, a price-to-earnings ratio of -5.15, a PEG ratio of 1.41 and a beta of 1.29. The firm has a 50-day moving average price of $15.72 and a two-hundred day moving average price of $13.64.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The company’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.19 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of Elanco Animal Health stock in a transaction dated Wednesday, March 6th. The stock was bought at an average cost of $16.14 per share, for a total transaction of $322,800.00. Following the purchase, the director now directly owns 185,000 shares in the company, valued at approximately $2,985,900. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Elanco Animal Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sapient Capital LLC bought a new stake in Elanco Animal Health in the 4th quarter valued at $2,046,000. Phocas Financial Corp. acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $3,857,000. Ancora Advisors LLC bought a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $37,189,000. UBS Group AG boosted its stake in shares of Elanco Animal Health by 78.2% in the third quarter. UBS Group AG now owns 681,905 shares of the company’s stock valued at $7,665,000 after buying an additional 299,166 shares during the period. Finally, Raymond James & Associates lifted its position in shares of Elanco Animal Health by 210.9% during the 3rd quarter. Raymond James & Associates now owns 1,015,294 shares of the company’s stock valued at $11,412,000 after acquiring an additional 688,779 shares during the period. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.